Skip to Main Content

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI)

Conditions

Diseases of the Cardiovascular System

Phase III

What is the purpose of this trial?

Brief Summary:

The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on the clinical outcome of renal impairment following transfusion of red blood cells (RBCs) treated with the INTERCEPT Blood System (IBS) for Red Blood Cells compared to patients transfused with conventional RBCs.

  • Trial with
    Cerus Corporation
  • Start Date
    08/14/2019
  • End Date
    01/30/2020
Trial Image

For more information about this study, contact:

Kimberly Kunze

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/05/2019
  • Study HIC
    #2000024812